VistaGen Therapeutics, Inc.
(NASDAQ : VTGN)

( )
VTGN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.00%183.551.1%$846.87m
GILDGilead Sciences, Inc.
0.00%80.700.9%$816.69m
CELGCelgene Corporation
0.00%95.261.2%$791.42m
JUNOJuno Therapeutics, Inc.
0.00%85.1013.5%$584.15m
BIIBBiogen Inc.
0.00%291.871.2%$500.99m
REGNRegeneron Pharmaceuticals, Inc.
0.00%332.152.7%$399.78m
VRTXVertex Pharmaceuticals Incorporated
0.00%160.721.9%$358.41m
ALXNAlexion Pharmaceuticals, Inc.
0.00%120.472.0%$256.63m
NKTRNektar Therapeutics
0.00%83.436.0%$246.17m
ILMNIllumina, Inc.
0.00%229.203.5%$234.08m
BLUEBluebird Bio, Inc.
0.00%213.3516.1%$201.76m
AAgilent Technologies, Inc.
0.00%71.941.5%$173.78m
INCYIncyte Corporation
0.00%86.032.5%$158.32m
EXASExact Sciences Corporation
0.00%48.8626.0%$132.16m
BMRNBioMarin Pharmaceutical Inc.
0.00%84.984.4%$122.34m

Company Profile

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system. Its product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2 development, initially for the adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to standard antidepressants. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.